Get the Stockscreener App
0.00
100.00%
-0.263
After Hours:
.2629
0.2629
+
Applied Molecular Transport Inc stock is currently priced at $0.00, with a 24-hour trading volume of 0.
It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.2788 pivot point. If it approaches the $0.1918 support level, significant changes may occur.
Previous Close:
$0.263
Open:
$0
24h Volume:
0
Market Cap:
$11.01M
Revenue:
-
Net Income/Loss:
$-74.79M
P/E Ratio:
0.00
EPS:
-2.38
Net Cash Flow:
$-60.49M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1D Range:
$0.00
$0.00
52W Range:
$0.00
$0.4893
Applied Molecular Transport Inc Stock (AMTI) Company Profile
Name
Applied Molecular Transport Inc
Sector
Industry
Phone
650 392 0420
Address
450 East Jamie Court, South San Francisco, CA
Applied Molecular Transport Inc Stock (AMTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-21 | Initiated | JMP Securities | Mkt Outperform |
| Jun-30-20 | Initiated | BofA Securities | Buy |
| Jun-30-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | SVB Leerink | Outperform |
Applied Molecular Transport Inc Stock (AMTI) Latest News
Applied Molecular Transport Inc Stock (AMTI) Financials Data
Applied Molecular Transport Inc (AMTI) Net Income 2024
AMTI net income (TTM) was -$74.79 million for the quarter ending September 30, 2023, a +44.16% increase year-over-year.
Applied Molecular Transport Inc (AMTI) Cash Flow 2024
AMTI recorded a free cash flow (TTM) of -$60.49 million for the quarter ending September 30, 2023, a +43.29% increase year-over-year.
Applied Molecular Transport Inc (AMTI) Earnings per Share 2024
AMTI earnings per share (TTM) was -$1.90 for the quarter ending September 30, 2023, a +45.09% growth year-over-year.
About Applied Molecular Transport Inc
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.
3.69%
0.93%
Cap:
|
Volume (24h):